# A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

> **NCT02684032** · PHASE1 · COMPLETED · sponsor: **Celcuity Inc** · enrollment: 141 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Gedatolisib
- **DRUG:** Palbociclib
- **DRUG:** Letrozole
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT02684032
- **Lead sponsor:** Celcuity Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-14
- **Primary completion:** 2022-01-19
- **Final completion:** 2022-01-19
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02684032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02684032, "A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02684032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*